Patents Issued in December 26, 2019
  • METHODS OF PREVENTION AND TREATMENT OF THROMBOSIS
    Publication number: 20190388406
    Abstract: Provided herein are methods for preventing and treating thrombosis in critically ill patients or in a patient being admitted to an intensive care unit by administering to the patient a therapeutically effective amount of betrixaban, or a pharmaceutically acceptable salt thereof, or a crystalline polymorph of betrixaban, or a crystalline polymorph of a pharmaceutically acceptable salt of betrixaban.
    Type: Application
    Filed: May 30, 2019
    Publication date: December 26, 2019
    Inventor: Olga Bandman
  • MULTIKINASE INHIBITORS OF VEGF AND TFG BETA AND USES THEREOF
    Publication number: 20190388407
    Abstract: A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, with associated angiogenesis and fibrosis, wherein the disease or disorder is selected from the group consisting of rosacea, psoriasis, erythema multiforme, bullous pemphigoid, hereditary hemorrhagic telangiectasia, rheumatoid arthritis, atopic dermatitis, and dermal wound healing. The pharmaceutical composition includes at least one multi-kinase inhibitor selected from the group consisting of axitinib, nintedanib, and lenvatinib.
    Type: Application
    Filed: February 12, 2017
    Publication date: December 26, 2019
    Inventors: Diane Tang-Liu, Gerald Woodrow DeVries
  • COMPLEXES OF LUMACAFTOR AND ITS SALTS AND DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20190388408
    Abstract: Disclosed herein are pharmaceutically acceptable complex formulations comprising complexes of Lumacaftor, or a salt, or derivative thereof together with complexation agents and, optionally, pharmaceutically acceptable excipients; processes for the preparation thereof and pharmaceutical compositions containing them. The complex formulations have improved dissolution and permeability in fasted and fed state simulation that is expected to deliver full absorption and the elimination of the food effect.
    Type: Application
    Filed: June 26, 2019
    Publication date: December 26, 2019
    Inventors: Richárd Balázs KÁRPÁTI, Betti SZABÓNÉ ORDASI, Orsolya BASA-DÉNES, Erzsébet Réka ANGI, Tamás JORDÁN, László MOLNÁR, Hristos GLAVINAS, Zsolt ÖTVÖS, Genovéva FILIPCSEI
  • Methods for Treatment of Fabry Disease
    Publication number: 20190388409
    Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
    Type: Application
    Filed: September 9, 2019
    Publication date: December 26, 2019
    Inventors: David J. Lockhart, Jeff Castelli
  • COMBINATIONS OF INHIBITORS OF IRAK4 WITH INHIBITORS OF BTK
    Publication number: 20190388410
    Abstract: The present application relates to novel combinations of at least two components, component A and component B: component A is an IRAK4-inhibiting compound of the formula (I) as defined herein, or a diastereomer, an enantiomer, a metabolite, a salt, a solvate or a solvate of a salt thereof; component B is a BTK-inhibiting compound, or a pharmaceutically acceptable salt thereof; and, optionally, one or more components C which are pharmaceutical products; in which one or two of the above-defined compounds A and B are optionally present in pharmaceutical formulations ready for simultaneous, separate or sequential administration, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis, lymphoma, macular degeneration, COPD, neoplastic disorders and psoriasis.
    Type: Application
    Filed: May 31, 2019
    Publication date: December 26, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Ulrich BOTHE, Antje Margret WENGNER, Holger SIEBENEICHER, Nicole SCHMIDT, Reinhard NUBBEMEYER, Ulf BÖMER, Judith GÜNTHER, Holger STEUBER, Martin LANGE, Christian STEGMANN, Andreas SUTTER, Roland NEUHAUS
  • NSAID ADMINISTRATION AND RELATED COMPOSITIONS, METHODS AND SYSTEMS
    Publication number: 20190388411
    Abstract: Described herein are methods and systems for treatment and/or prevention of conditions associated with NSAID administration and related compositions.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 26, 2019
    Inventors: Giuseppe Claudio VISCOMI, Maria GRIMALDI, Maria Vittoria FOGLI, Paola MAFFEI, Cecilia RENZULLI, Annalisa SFORZINI, Corrado BLANDIZZI, Carmelo SCARPIGNATO
  • ILOPERIDONE FOR THE TREATMENT OF SCHIZOPHRENIA
    Publication number: 20190388412
    Abstract: Aspects of the invention relate generally to the treatment of schizophrenia in an individual and, more specifically, to the treatment of an individual with iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof. In one embodiment, the invention provides a method of preventing schizophrenic relapse in an individual diagnosed with schizophrenia, the method comprising: administering to the individual iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof at a daily dose between about 12 mg and about 16 mg following a period in which the individual's schizophrenia was stabilized.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 26, 2019
    Inventors: Mihael H. Polymeropoulos, Curt D. Wolfgang
  • COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS
    Publication number: 20190388413
    Abstract: Provided herein are methods of treating and/or preventing endometriosis or symptom thereof, assays for diagnosing/prognosing endometriosis, compositions and formulations for treating and/or preventing endometriosis or symptom thereof, and populations of endometiotic cells, including life-extended populations of cells.
    Type: Application
    Filed: November 18, 2015
    Publication date: December 26, 2019
    Applicants: University of South Florida, PONCE HEALTH SCIENCES UNIVERSITY
    Inventors: MEERA NANJUNDAM, KYLE A. BAUCKMAN, IDHALIZ FLORES
  • RORGAMMA MODULATORS AND USES THEREOF
    Publication number: 20190388414
    Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
    Type: Application
    Filed: January 29, 2018
    Publication date: December 26, 2019
    Inventors: Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
  • SUBSTITUTED DIHYDROBENZOFURAN GLYCOSIDASE INHIBITORS
    Publication number: 20190388415
    Abstract: Compounds of formula (I), wherein R?, R?, R, X, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Application
    Filed: August 24, 2017
    Publication date: December 26, 2019
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI
  • CONCENTRATED, INHALABLE CIPROFLOXACIN FORMULATION
    Publication number: 20190388416
    Abstract: A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.
    Type: Application
    Filed: August 14, 2019
    Publication date: December 26, 2019
    Applicant: ARADIGM CORPORATION
    Inventors: DAVID C. CIPOLLA, James BLANCHARD
  • PHARMACEUTICAL COMPOSITIONS CONTAINING AZAQUINONE FOR INHIBITING CLOSTRIDIUM DIFFICILE ACTIVITY
    Publication number: 20190388417
    Abstract: Methods for inhibiting the activity of Clostridium difficile in a subject comprises administering to the subject in need thereof, a therapeutically effective amount of azaquinone or a pharmaceutical composition consisting of clofazimine or a clofazimine analogue, azaquinone, and at least one pharmaceutically acceptable excipient. Pharmaceutical compositions comprising a therapeutically effective amount of azaquinone or consisting of clofazimine or a clofazimine analogue, azaquinone, and at least one pharmaceutically acceptable excipient are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.
    Type: Application
    Filed: August 21, 2019
    Publication date: December 26, 2019
    Applicant: KamTek, Inc.
    Inventors: Venkata M. Reddy, Wolf Prensky, Sharanjit VedBrat
  • AMORPHOUS SOLID DISPERSIONS
    Publication number: 20190388418
    Abstract: The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 3, 2017
    Publication date: December 26, 2019
    Inventor: Peng LI
  • SYK INHIBITORS
    Publication number: 20190388419
    Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.
    Type: Application
    Filed: May 15, 2019
    Publication date: December 26, 2019
    Inventors: Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee, Jennifer R. Lo, Scott A. Mitchell, Aaron C. Schmitt, Sundaramoorthi Swaminathan, Jin-Ming Xiong, Jianjun Xu, Zhongdong Zhao
  • TUMOR-TREATING PHARMACEUTICAL COMPOSITION
    Publication number: 20190388420
    Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.
    Type: Application
    Filed: February 6, 2018
    Publication date: December 26, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yoichi Ozawa, Yusaku Hori, Kazuhiko Yamada, Hiroshi Kamiyama, Masahiro Matsuki
  • NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS
    Publication number: 20190388421
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6a, X, Cy1, Cy2, and the subscript n and m are as defined herein. The present invention relates to antagonists compounds of sphingosine 1-phosphate (S1P) receptor, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, inflammatory diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, and/or proliferative diseases by administering the compound of the invention.
    Type: Application
    Filed: February 23, 2017
    Publication date: December 26, 2019
    Inventors: Oscar MAMMOLITI, Koen Karel JANSEN, Adeline Marie Elise PALISSE, Caroline Martine Andrée Marie JOANNESSE, Christel Jeanne Marie MENET, Brigitte ALLART, Sandy EL BKASSINY
  • PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES
    Publication number: 20190388422
    Abstract: The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug.
    Type: Application
    Filed: September 5, 2019
    Publication date: December 26, 2019
    Inventors: Lawrence Helson, George M. Shopp, Annie Bouchard, Muhammed Majeed
  • Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor
    Publication number: 20190388423
    Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxy-anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 26, 2019
    Applicant: Merck Patent GmbH
    Inventors: Friedhelm BLADT, Manja FRIESE-HAMIM
  • ANTI-CANCER COMPOSITION CONSISTING OF HALOFUGINONE AND SESQUITERPENE LACTONE COMPOUNDS OF ARTEMISIA APIACEA AND USE THEREOF
    Publication number: 20190388424
    Abstract: Provided is a combined pharmaceutical composition of HF and an Artemisia annua sesquiterpene lactone compound for treating cancers. The active ingredients of the combined pharmaceutical composition consist of HF and an Artemisia annua sesquiterpene lactone compound. HF and ATS have significant synergistic effect. The activity of the combined pharmaceutical of HF and ATS is comparable or even higher than that of the anti-cancer drug 5-FU.
    Type: Application
    Filed: September 27, 2016
    Publication date: December 26, 2019
    Inventors: Zhaoxiang BIAN, Guoqing CHEN, Ruihong GONG, Dajian YANG, Aiping LYU
  • SUBSTITUTED IMIDAZOPYRIDINPYRIMIDINES
    Publication number: 20190388425
    Abstract: The present invention relates to substituted imidazopyridinpyrimidine compounds of general formula (I) which inhibit MKNK1 and MKNK2 kinase (also known as MAP Kinase interacting Kinase, Mnk1 and Mnk2), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: January 19, 2018
    Publication date: December 26, 2019
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Ulrich KLAR, Heike SCHÄCKE, Detlev SÜLZLE, Stephan MENZ
  • PERK AND IRE-1A INHIBITORS AGAINST NEURODEVELOPMENTAL DISORDERS
    Publication number: 20190388426
    Abstract: The present invention relates to UPR pathway inhibitors, in particular PERK and IRE-1 A inhibitors for use in the prevention or treatment of neurodevelopmental disorders, such as microcephaly caused by ZIKV.
    Type: Application
    Filed: January 29, 2018
    Publication date: December 26, 2019
    Inventors: Laurent NGUYEN, Catherine CREPPE, Christian ALFANO, Ivan GLADWYN-NG, Lluis Cordon BARRIS
  • STABLE 5-METHYLTETRAHYDROFOLATE FORMULATIONS TO MODERATE METHYLENETETRAHYDROFOLATE REDUCTASE ASSOCIATED POLYMORPHISMS
    Publication number: 20190388427
    Abstract: Provided herein are methods for preparing stable solutions containing 5-methyltetrahydrofolate (MTHF). Also provided herein are stable compositions containing calcium 5-methyltetrahydrofolate (MTHF-Ca).
    Type: Application
    Filed: September 4, 2019
    Publication date: December 26, 2019
    Inventors: Debra K. Hubers, Christine A. Givant
  • A Pharmaceutical Composition Comprising An Oxazine Derivative And Its Use In The Treatment Or Prevention Of Alzheimer's Disease
    Publication number: 20190388428
    Abstract: The present invention relates to a pharmaceutical composition comprising an oxazine derivative BACE-1 inhibitor, a process for the preparation thereof, and its use in the treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: January 18, 2018
    Publication date: December 26, 2019
    Inventors: Miloud Achour, Brumo Galli, Edgar John, Michael Juhnke, Dragutin Knezic, Vishal Shamji Koradia, Rita Ramos
  • METHODS OF TREATING CANCER USING 3-(4-((4-(MORPHOLINOMETHYL)BENZYL)OXY)-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE
    Publication number: 20190388429
    Abstract: Provided herein are methods of treating, preventing and/or managing cancers, which comprise administering to a patient 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Application
    Filed: August 1, 2019
    Publication date: December 26, 2019
    Inventors: Peter H. Schafer, Anita Gandhi
  • OPIOID AND ANTIEMETIC COMBINATION COMPOSITIONS FOR INCREASED PAIN RELIEF
    Publication number: 20190388430
    Abstract: Provided herein are methods for pain relief comprising administering to a subject in need thereof a solid oral pharmaceutical composition having an opioid analgesic and an antiemetic. The solid oral pharmaceutical composition may provide for increased pain relief when administered in comparison to administration of solid oral pharmaceutical composition having an opioid analgesic but lacking the antiemetic.
    Type: Application
    Filed: December 4, 2018
    Publication date: December 26, 2019
    Inventors: Paul BOSSE, John AMELING, Bernard SCHACHTEL, William KOZAREK
  • TWO-COMPONENT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PAIN
    Publication number: 20190388431
    Abstract: The present invention is directed to a pharmaceutical composition that includes a combination of about 2-5 milligrams of a non-steroidal anti-inflammatory drug and from about 2-30 milligrams of an opioid analgesic in a single pharmaceutical dosage unit that can provide effective chronic pain management with the added benefit of reduced side effects such as withdrawal and gastrointestinal disorders. The non-steroidal anti-inflammatory drug may be piroxicam and the opioid analgesic may be buprenorphine. The present invention also provides for a method of managing pain in a patient that includes administering the pharmaceutical composition previously described. The pharmaceutical composition previously described may be administered in a single or multiple dosage regimen.
    Type: Application
    Filed: December 21, 2018
    Publication date: December 26, 2019
    Applicant: BRIDGE THERAPEUTICS, INC.
    Inventors: Alton Samuel KELLEY, II, James Gregory SULLIVAN
  • MIDAZOLAM IN FLEXIBLE BAGS
    Publication number: 20190388432
    Abstract: Terminally sterilized, preservative-free aqueous midazolam solution comprising 0.25 to 1.5 mg/ml of midazolam, a tonicity adjusting agent to provide an osmolality of from 260 and 320 mosm/kg and sufficient acid and optionally a base to provide a pH of from about 2.5 to 3.5 with the remainder water for injection packaged in a flexible plastic container.
    Type: Application
    Filed: June 20, 2018
    Publication date: December 26, 2019
    Applicant: InfoRLife SA
    Inventor: Sergio DUSCI
  • PREVENTION OF PRETERM BIRTH (PTB) BY INHIBITION OF FKBP51
    Publication number: 20190388433
    Abstract: The disclosure is directed to a method of enhancing progesterone receptor (PR) activity in a mammal, which comprises administering a composition comprising an inhibitor of FK506 binding protein 51 (FKBP51) to a mammal in need thereof, such as a pregnant human female, whereby progesterone receptor activity in the mammal is enhanced as compared to a mammal not administered the composition. The method results in an extension of the gestation period and a decreased likelihood of preterm birth and fetal growth restriction.
    Type: Application
    Filed: February 23, 2018
    Publication date: December 26, 2019
    Inventors: Charles Lockwood, Özlem Guzeloglu-Kayisli, Ümit Kayisli, Frederick Schatz
  • (17-ß)-3-Oxoandrost-4-En-17-Yl Undecanoate Compositions and Methods of Their Preparation and Use
    Publication number: 20190388434
    Abstract: Disclosed herein are compositions having a lipophilic active agent and methods of their use.
    Type: Application
    Filed: May 30, 2019
    Publication date: December 26, 2019
    Applicant: Lipocine Inc.
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish Kumar Nachaegari, Srinivansan Venkateshwaran, Joel Frank, Amy Jo Portlock
  • PHARMACEUTICAL FORMULATIONS AND USES THEREOF IN THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION
    Publication number: 20190388435
    Abstract: The present invention relates to the use of a combination of a PDE5-inhibitor and testosterone for the preparation of a medicament for the treatment of Female Sexual Dysfunction.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 26, 2019
    Applicant: EB IP LYBRIDO B.V.
    Inventor: Jan Johan Adriaan TUITEN
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20190388436
    Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one beclomethasone compound selected from beclomethasone and the pharmaceutically acceptable derivatives thereof and at least one long acting beta-2-agonist; (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a); and (iii) glycerol.
    Type: Application
    Filed: September 18, 2017
    Publication date: December 26, 2019
    Inventors: Stuart CORR, Timothy James NOAKES
  • COMPOSITIONS AND METHODS FOR TREATING BONE AND JOINT INFECTIONS
    Publication number: 20190388437
    Abstract: The invention described herein pertains to the treatment of infections arising in bones and/or joints. The invention described herein also pertains to the treatment of infections arising from implants and prostheses. Bone and joint infections (BJIs) represent a serious medical condition that, if untreated, can lead to complete loss or loss of use of bones or joints in the patient, and even death. BJIs include many diseases, such as acute and chronic osteomyelitis, including pediatric osteomyelitis, septic arthritis, and others.
    Type: Application
    Filed: February 19, 2019
    Publication date: December 26, 2019
    Inventor: Prabhavathi FERNANDES
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20190388438
    Abstract: A pharmaceutical composition is described. The composition comprises at least one mometasone compound selected from mometasone, pharmaceutically acceptable salts of mometasone, prodrugs of mometasone, solvates of mometasone, solvates of pharmaceutically acceptable salts of mometasone and solvates of prodrugs of mometasone and a propellant component comprising 1,1-difluoroethane (R-152a). In a preferred embodiment, the composition further comprises at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol.
    Type: Application
    Filed: September 9, 2019
    Publication date: December 26, 2019
    Inventors: Stuart Corr, Timothy James Noakes
  • PHARMACEUTICAL SPRAY COMPOSITION COMPRISING A VITAMIND D ANALOGUE AND A CORTICOSTEROID
    Publication number: 20190388439
    Abstract: The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative or analogue and a corticosteroid, and its use in the treatment of dermal diseases and conditions.
    Type: Application
    Filed: August 28, 2019
    Publication date: December 26, 2019
    Inventors: Marianne LIND, Gritt RASMUSSEN, Mette Rydahl SONNE, Jens HANSEN, Karsten PETERSSON
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION
    Publication number: 20190388440
    Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.
    Type: Application
    Filed: September 5, 2019
    Publication date: December 26, 2019
    Inventors: Yair ALSTER, Omer RAFAELI, K. Angela MACFARLANE, Cary REICH, Shimon AMSELEM, Doron FRIEDMAN
  • NOVEL PRODRUGS OF MIZORIBINE
    Publication number: 20190388441
    Abstract: The present invention relates to novel prodrugs of mizoribine, and a method for their preparation, as well as to pharmaceutical compositions comprising these prodrugs and one or more pharmaceutically acceptable excipients. The present invention further relates to the use of said novel prodrugs as biologically active ingredients, specifically in combination with other biologically active drugs such as immunosuppressants and/or immunomodulatory drugs, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and autoimmune disorders, organ and cells transplant rejection.
    Type: Application
    Filed: January 22, 2018
    Publication date: December 26, 2019
    Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Piet Herdewijn, Ling-Jie Gao, Yuan Lin, Mark Waer
  • Acyclic Nucleoside Phosphonate Diesters
    Publication number: 20190388442
    Abstract: The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.
    Type: Application
    Filed: September 11, 2019
    Publication date: December 26, 2019
    Inventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
  • COMPOSITION COMPRISING KETONE BODY AND NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATOR AND METHYL DONOR
    Publication number: 20190388443
    Abstract: The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 26, 2019
    Inventor: Michael A. Schmidt
  • SURFACTANT FORMULATIONS FOR INHALATION
    Publication number: 20190388444
    Abstract: The present invention is directed respirable, dry powder particle formulations of lung surfactants that optionally comprise surfactant proteins and that are formulated for delivery to the pulmonary system via inhalation.
    Type: Application
    Filed: December 21, 2018
    Publication date: December 26, 2019
    Inventors: Michael M. Lipp, Abhijit Kamerkar, Fahad Gilani, Holly Chan, Michael Tauber
  • COMPOSITION WITH NON-DIGESTIBLE OLIGOSACCHARIDES FOR ATTENUATING NASAL EPITHELIAL INFLAMMATION
    Publication number: 20190388445
    Abstract: The present invention relates to the use of non-digestible oligosaccharides for the direct attenuation of nasal epithelial inflammation, in particular for non-allergic rhinitis, in particular for use in infants.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 26, 2019
    Inventors: Jeroen VAN BERGENHENEGOUWEN, Johan GARSSEN, Claudia TRAIDL-HOFFMANN, Caroline SCHLUMPRECHT
  • METHOD OF USING NEOANDROGRAPHOLIDE FOR LOWERING BLOOD SUGAR, LOWERING BLOOD LIPID, IMPROVING LIVER FUNCTION AND IMRPOVING RENAL FUNCTION
    Publication number: 20190388446
    Abstract: A method of using Neoandrographolide for lowering blood sugar, lowering blood lipid, improving liver function and improving renal function. The method includes preparing a composition comprising Neoandrographolide as the active ingredient, and administering the composition to lower the blood sugar or blood lipid of a user, to prevent a decrease in liver function of a user, or to improve the renal function of a user. The Neoandrographolide is the only active ingredient in the composition.
    Type: Application
    Filed: June 22, 2019
    Publication date: December 26, 2019
    Applicant: Bioalpha International Sdn. Bhd.
    Inventors: Yu-Chin Lin, Ching-Wen Chang
  • GLYCAN-BASED DRUGS, THERAPIES AND BIOMARKERS
    Publication number: 20190388447
    Abstract: The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and products for the diagnosis, prevention, and treatment of such diseases obtainable based on these therapeutic targets can be developed.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 26, 2019
    Inventor: Huiru WANG
  • COMPOSITION FOR COUGH
    Publication number: 20190388448
    Abstract: The present invention relates to a new composition for use in the treatment of cough comprising one or more polysaccharide fractions of plantain, one or more polysaccharide fractions of marshmallow, honey, brown sugar, one or more polyphenolic fractions of agrimony comprising tannins.
    Type: Application
    Filed: February 12, 2018
    Publication date: December 26, 2019
    Applicant: Aboca S.p.A. Società Agricola
    Inventors: Valentino MERCATI, Luisa MATTOLI, Paola POLENZANI
  • PHARMACEUTICAL COMPOSITION COMPRISING QUERCETIN-3-O-BETA-D-XYLOPYRANOSIDE FOR PREVENTING OR TREATING LIVER DISEASE
    Publication number: 20190388449
    Abstract: Provided is a pharmaceutical composition including quercetin-3-O-?-D-xylopyranoside for preventing or treating a liver disease. Since the composition has an effect on inhibiting alcohol-induced accumulation of triglycerides in the blood and liver, having no toxicity and without affecting feed intake, body weight, organ weight, and the like, the composition of the present invention may be efficiently utilized as a pharmaceutical composition for preventing and treating a liver disease such as steatosis, hepatitis, hepatic fibrosis, and cirrhosis or a health functional food for preventing or alleviating a liver disease such as steatosis, hepatitis, hepatic fibrosis, and cirrhosis.
    Type: Application
    Filed: November 13, 2017
    Publication date: December 26, 2019
    Inventors: Sun Young Kim, Yong Jun Lee, Dong Joo Kwon, Young Han Kim
  • Compositions And Methods For Immunotherapy
    Publication number: 20190388450
    Abstract: The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become obligately anerobic and cellular proliferative disorders including cancer. The immunotherapeutics herein use benzaldehyde derivatives, precursors and intermediaries alone or in combination with additional therapeutic agents to stimulate the immune system and inhibit cellular proliferation.
    Type: Application
    Filed: August 30, 2019
    Publication date: December 26, 2019
    Inventor: Joe Ernest BROWN
  • IDOXURIDINE AND ITS ANALOGS AS NEUROPROTECTANS FOR THE TREATMENT OF PARKINSONISM
    Publication number: 20190388451
    Abstract: The invention relates to compounds that are useful in the treatment of parkinsonism, such as parkinsonism in connection with Parkinson's disease (PD); dementia with Lewy bodies (DLB); multiple system atrophy (MSA); corticobasal degeneration (CBD); or progressive supranuclear palsy (PSP). The said compounds include in particular idoxuridineand analogs thereof as well as their metabolic precursors, such as ropidoxuridine. The invention further relates to method for identifying compounds useful for the treatment of parkinsonism, said methods comprising detecting the capability of compound to increase the amount of GPR37 in cell membranes. The invention further relates to methods for the chemical synthesis of ropidoxuridine.
    Type: Application
    Filed: February 6, 2018
    Publication date: December 26, 2019
    Inventors: Per Svenningsson, Lina Leinartaite, Magdalena Otrocka, Vedran Hasimbegovic, Birgitta Pettersson
  • PRODRUG COMPOUNDS AND THEIR USES
    Publication number: 20190388452
    Abstract: Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver.
    Type: Application
    Filed: August 30, 2019
    Publication date: December 26, 2019
    Inventor: Lin Zhi
  • TREATMENT OF DRUG RESISTANT PROLIFERATIVE DISEASES WITH TELOMERASE MEDIATED TELOMERE ALTERING COMPOUNDS
    Publication number: 20190388453
    Abstract: The described invention is directed toward pharmaceutical compositions and methods of using 6-mercaptopurine ribosides and analogues thereof for the treatement of cancer and other hyperproliferative diseases. The described compounds can be converted into telomere substrates in vivo and can be recognized by telomerase for incorporation into telomeres of telomerase active cells, leading to induction of cell death of the telomerase active cells.
    Type: Application
    Filed: June 24, 2019
    Publication date: December 26, 2019
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Jerry SHAY, Ilgen MENDER, Kimberly BATTEN
  • METHODS FOR TREATING NLRP3 INFLAMMASOME-ASSOCIATED DISEASES, AND METHODS OF IDENTIFYING AGENTS USEFUL THEREFOR
    Publication number: 20190388454
    Abstract: Provided herein are methods of treating NLRP3 inflammasome-associated diseases and disorders. Also, disclosed are methods for screening for agents useful in such methods.
    Type: Application
    Filed: June 25, 2019
    Publication date: December 26, 2019
    Inventors: Michael Karin, Zhenyu Zhong
  • Dosage Form for Treating Severe Asthma
    Publication number: 20190388455
    Abstract: Methods are provided for treating corticosteroid-resistant asthma in a patient, comprising decreasing Interferon Regulatory Factor 5 (IRF5) activity in the patient. Antisense or RNA interference reagents and methods can be used to decrease IRF5 activity in the patient.
    Type: Application
    Filed: August 13, 2019
    Publication date: December 26, 2019
    Inventors: Anuradha Ray, Prabir Ray, Timothy B. Oriss, Sally Ellen Wenzel